Fig. 2: Passive immunisation with mAbs against S. aureus.

a Panel of mAbs obtained after immunisation of BALB/c mice with S. aureus rCgoX and rTPI. Protectivity was evaluated after passive immunisation and subsequent challenge of BALB/c mice (n = 10) with a lethal dose of S. aureus ATCC 29213. b BALB/c mice were passively immunised i.p. with 200 µg of the indicated mAbs (or with PBS as control) and subsequently challenged with 1 × 10⁶ cfu S. aureus strain USA300 i.p. Significance was calculated by Log-rank (Mantel-Cox) test. c BALB/c mice were passively immunised i.p. with 300 µg of the indicated mAbs (or with PBS as control) and subsequently challenged with 5 × 10⁵ cfu S. aureus strain ATCC 29213 i.p. Significance was calculated by Log-rank (Mantel-Cox) test. d Specific binding of mAbs to their corresponding recombinant antigen. A His₆-tagged unrelated S. aureus protein, rABH2140-His, was used as control). e Cross reactivity analysis of mAbs with human and murine cell lysates. 20 ng of purified, rCgoX or rTPI (lane 1), 2 µg of HeLa cell lysate (lane 2), 2 µg of THP-1 cell lysate (lane 3) and 2 µg of MEF cell lysate (lane 4) were separated by SDS-PAGE and analysed by staining with indicated mAbs. f Representative proliferation study of WT and CgoX-deficient (ΔCgoX) S. aureus strain USA300 JE2. g Growth curves of S. aureus strain USA300 JE pre-incubated with the indicated mAbs (n = 4 biological replicates). Experiments are respresentatives of three independent experiments.